Longeveron Announces Engagement of Lucid Capital Markets

Longeveron has retained Lucid Capital Markets as financial advisor to explore potential strategic opportunities, including a possible business combination. The company is a clinical-stage biotech whose lead asset, laromestrocel (Lomecel-B), holds five FDA designations across its HLHS and Alzheimer's programs.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.